Abstract
Hypoxia-inducible factor (HIF)-1α is over-expressed in hepatocellular carcinoma (HCC) and degraded by ubiquitin-proteasome pathways under normoxic conditions. Hepatocyte hypoxia enhances proliferation, angiogenesis, metastasis, chemoresistance, and radioresistance of HCC. The importance role of HIF-1α expression in HCC may improve the prognostic and therapeutic technique. This article reviews the HIF-1α expression and its gene during the rat HCC development, the level of HIF-1α expression in HCC patients, and the effect of silencing HIF-1α gene by miRNA on inhibition of HepG2 cell proliferation.
Keywords: Hepatocellular carcinoma, hypoxia-inducible factor-1alpha, vascular endothelial growth factor, angiopoietin-2, and molecular-targeted therapy.
Mini-Reviews in Medicinal Chemistry
Title:Hypoxia-inducible Factor-1alpha: Molecular-targeted Therapy for Hepatocellular Carcinoma
Volume: 13 Issue: 9
Author(s): Z. Z. Dong, M. Yao, L. Wang, W. Wu, X. Gu and D. F. Yao
Affiliation:
Keywords: Hepatocellular carcinoma, hypoxia-inducible factor-1alpha, vascular endothelial growth factor, angiopoietin-2, and molecular-targeted therapy.
Abstract: Hypoxia-inducible factor (HIF)-1α is over-expressed in hepatocellular carcinoma (HCC) and degraded by ubiquitin-proteasome pathways under normoxic conditions. Hepatocyte hypoxia enhances proliferation, angiogenesis, metastasis, chemoresistance, and radioresistance of HCC. The importance role of HIF-1α expression in HCC may improve the prognostic and therapeutic technique. This article reviews the HIF-1α expression and its gene during the rat HCC development, the level of HIF-1α expression in HCC patients, and the effect of silencing HIF-1α gene by miRNA on inhibition of HepG2 cell proliferation.
Export Options
About this article
Cite this article as:
Dong Z. Z., Yao M., Wang L., Wu W., Gu X. and Yao F. D., Hypoxia-inducible Factor-1alpha: Molecular-targeted Therapy for Hepatocellular Carcinoma, Mini-Reviews in Medicinal Chemistry 2013; 13 (9) . https://dx.doi.org/10.2174/1389557511313090004
DOI https://dx.doi.org/10.2174/1389557511313090004 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: From a Clinical to a Molecular Association
Current Pharmaceutical Design MicroRNAs in Tumorigenesis
Current Pharmaceutical Biotechnology The Origin of Lentivirus Research: Maedi-Visna Virus
Current HIV Research Targeted Therapies in Head and Neck Cancer: Past, Present and Future
Reviews on Recent Clinical Trials The Coordinated Role of CYP450 Enzymes and P-gp in Determining Cancer Resistance to Chemotherapy
Current Drug Metabolism Interplay between Epigenetics & Cancer Metabolism
Current Pharmaceutical Design Autophagy and Cell Death in Caenorhabditis elegans
Current Pharmaceutical Design Aurora B: A New Prognostic Marker and Therapeutic Target in Cancer
Current Medicinal Chemistry Antineoplastic Potential of Medicinal Plants
Recent Patents on Biotechnology Synthetic Methods of Quinoline Derivatives as Potent Anticancer Agents
Mini-Reviews in Medicinal Chemistry Gene Therapeutic Approaches for Immune Modulation in AIDS
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Protein-Protein Interaction Inhibitors: Small Molecules from Screening Techniques
Current Topics in Medicinal Chemistry Roles of Casein Kinase I η and δ in Gastrointestinal Cancers: Potential New Screening Markers and Drug Targets
Current Cancer Therapy Reviews circEPSTI1 Acts as a ceRNA to Regulate the Progression of Osteosarcoma
Current Cancer Drug Targets Roles of EGFR, PI3K, AKT, and mTOR in Heavy Metal-Induced Cancer
Current Cancer Drug Targets NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization
Current Pharmaceutical Design Current Status of Gene Therapy for Hepatocellular Carcinoma, with a Focus on Gene Delivery Approaches
Current Gene Therapy Stem Cell Transplantation in Pediatric Leukemia and Myelodysplasia: State of the Art and Current Challenges
Current Stem Cell Research & Therapy The Role of Fibroblast Growth Factors in Tumor Growth
Current Cancer Drug Targets Tracking Stem Cell Therapy in the Myocardium: Applications of Positron Emission Tomography
Current Pharmaceutical Design